Regenxbio shares are trading higher after RBC Capital upgraded the stock from Sector Perform to Outperform and raised its price target from $20 to $35.
Portfolio Pulse from Benzinga Newsdesk
Regenxbio's stock (RGNX) experienced a price increase following an upgrade by RBC Capital from Sector Perform to Outperform, along with a raised price target from $20 to $35.
March 08, 2024 | 1:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regenxbio's stock received a positive outlook from RBC Capital, upgrading it to Outperform and increasing the price target to $35.
The upgrade by RBC Capital to Outperform signifies a strong confidence in Regenxbio's future performance. The significant raise in the price target from $20 to $35 reflects an optimistic outlook on the stock's value, likely leading to increased investor interest and potentially higher stock prices in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100